Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
5(100.0%)
5Total
N/A(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05829733Not ApplicableRecruiting

6-month Efficacy and Safety of Synolis VA 80/160 in Hip Osteoarthritis

Role: lead

NCT05337540Not ApplicableCompleted

A Study to Evaluate the Efficacy, Safety and Tolerability of EVI-01 Intra-Articular Injection in Osteoarthritis of the Knee

Role: lead

NCT05422976Not ApplicableCompleted

EVI-01-IT Safety Study

Role: lead

NCT05829798Not ApplicableCompleted

An Efficacy and Safety 6-months Study of SYNOLIS VA 80/160 and SYNOLIS VA 40/80 in the Treatment of Symptomatic Knee Osteoarthritis

Role: lead

NCT05829850Not ApplicableCompleted

An Effectiveness and Safety 6 Months Study of 3 Injections One Week Apart of SYNOLIS VA 40/80 in the Treatment of Symptomatic Knee Osteoarthritis

Role: lead

All 5 trials loaded